Delcath Systems Inc (DCTH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Delcath Systems Inc stock (DCTH) is currently trading at $8.98. Delcath Systems Inc PE ratio is 129.57. Delcath Systems Inc PS ratio (Price-to-Sales) is 3.76. Analyst consensus price target for DCTH is $21.33. WallStSmart rates DCTH as Sell.
- DCTH PE ratio analysis and historical PE chart
- DCTH PS ratio (Price-to-Sales) history and trend
- DCTH intrinsic value — DCF, Graham Number, EPV models
- DCTH stock price prediction 2025 2026 2027 2028 2029 2030
- DCTH fair value vs current price
- DCTH insider transactions and insider buying
- Is DCTH undervalued or overvalued?
- Delcath Systems Inc financial analysis — revenue, earnings, cash flow
- DCTH Piotroski F-Score and Altman Z-Score
- DCTH analyst price target and Smart Rating
Delcath Systems Inc
📊 No data available
Try selecting a different time range
DCTH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Delcath Systems Inc (DCTH)
DCTH trades 1879% above its Graham fair value of $0.48, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Delcath Systems Inc (DCTH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Delcath Systems Inc (DCTH) Key Strengths (2)
Revenue surging 37.30% year-over-year
50.77% held by institutions, strong professional interest
Supporting Valuation Data
Delcath Systems Inc (DCTH) Areas to Watch (8)
Losing money on operations
Earnings declining -66.70%, profits shrinking
Very low returns on shareholder equity
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Growth is fairly priced, not cheap, not expensive
Revenue is fairly priced at 3.76x sales
Fairly priced relative to book value
Supporting Valuation Data
Delcath Systems Inc (DCTH) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.0/10) while 8 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 37.30%.
The Bear Case
The primary concerns are Operating Margin, EPS Growth, Return on Equity. Some valuation metrics including PEG Ratio (1.60), Price/Sales (3.76), Price/Book (2.83) suggest expensive pricing. Growth concerns include EPS Growth at -66.70%, which may limit upside. Profitability pressure is visible in Return on Equity at 3.00%, Operating Margin at -10.50%, Profit Margin at 3.17%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 3.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 37.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DCTH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DCTH's Price-to-Sales ratio of 3.76x trades at a deep discount to its historical average of 73.66x (25th percentile). The current valuation is 99% below its historical high of 379.68x set in Feb 2021, and 4076% above its historical low of 0.09x in Apr 2018.
WallStSmart Analysis Synopsis
Data-driven financial summary for Delcath Systems Inc (DCTH) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Delcath Systems Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 85M with 37% growth year-over-year. Profit margins are strong at 317.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 37% YoY, reaching 85M. This pace significantly outperforms most MEDICAL DEVICES peers.
ROE of 300.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Earnings fell 67% YoY while revenue grew 37%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Delcath Systems Inc maintain 37%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 129.6x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Delcath Systems Inc.
Bottom Line
Delcath Systems Inc offers an attractive blend of growth (37% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Delcath Systems Inc(DCTH)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.